ClinicalTrials.gg
RecruitingNCT06015256NKASUpdated Oct 29, 2026

Characterization of Natural Killer Cells in Severe Asthma Patients in Comparison With Control Subjects

An interventional study of blood sample in Asthma Acute, sponsored by Institut National de la Santé Et de la Recherche Médicale, France. Recruiting at 1 site in France. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-29.

Sponsored by Institut National de la Santé Et de la Recherche Médicale, France · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Started Sep 2023; still recruiting 3 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
448
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 296 studies in Asthma with a site in France — 44 open to participants now, 57 under way, 8 of them phase 3. Asthma · France.

Planned enrollment
60th of 204
448 · median 209
Started
2023
with 24 others
No phase
63 of 296
17 open now
Primary completion
2028-09
later than 41 of 56 live
Registered
256th of 296
by date

Among the 296 studies in Asthma with a site in France, this one is the 60th largest by planned enrollment of the 204 interventional ones that give a count, is one of 25 that started in 2023, is one of 63 with no phase, reaches primary completion later than 41 of the 56 other live ones, and was the 256th registered.

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

Browse Asthma studies →

Open to participants now

44 of the 296 studies in Asthma with a site in France are open now. Recruiting first, the newest first:

38 more — sign in →

All 44 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 416 Asthma studies recruiting now, 141 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 146 take children under 18; 105 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 296 studies in Asthma with a site in France, or all of them as a file.
02

Study summary

Asthma is a common chronic bronchial disease affecting 300 million people worldwide. The disease can be severe when it is not managed properly or when it is not controlled by treatments. Asthma is characterized by bronchial inflammation, bronchial hyperreactivity and tissue remodeling. Symptoms include episodes of coughing, dyspnoea and wheezing in relation with bronchial obstruction. The evolution is marked by the occurrence of exacerbations (increase of symptoms), most often triggered by viral infections, mostly due to rhinoviruses. The treatment of asthma is based on inhaled corticosteroid therapy sometimes combined with other treatments that help control the majority of asthma. However, about 10% of patients suffer from persistent symptoms despite these treatments.

Natural killer (NK) cells are important actors of the antiviral innate immune response and are present in high numbers in the lungs. However, their role in severe asthma and its virus-induced exacerbations is unknown.

The purpose of this work is to characterize NK cells in severe asthma in order to identify molecules expressed differently from control subjects. The goal is to assess whether these molecules could be potential biomarkers of a severe asthma subtype, also known as the endotype, and/or be the molecular control for exacerbation. The advantage of identifying biomarkers for inflammatory diseases lies in their usefulness in establishing a correct diagnosis, monitoring the progress of the disease and the effectiveness of treatments. The secondary objectives are to characterize the activation of NK cells in response to in vitro rhinovirus infection of different types, in monoculture or in a model of interaction with a bronchial epithelium, and identify one or more molecules involved in the interaction between bronchial epithelial cells and NK cells.

03

Conditions studied

  • Asthma Acute

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria:

Cases asthma controlled, uncontrolled excluding exacerbation, uncontrolled asthma exacerbation, and healthy volunteers:

  • Consent form read, understood, approved and signed before any study procedure
  • Membership of a social security scheme or beneficiary of such a scheme
  • Patient aged over 18

Cases asthma controlled, uncontrolled excluding exacerbation, uncontrolled exacerbation:

- Diagnosis of severe asthma confirmed by a respirologist at an expert centre

Case asthma controlled:

- Asthma control confirmed by a lung specialist from an expert centre

Case uncontrolled asthma excluding exacerbation:

- Uncontrolled asthma confirmed by a lung specialist from an expert centre

Case uncontrolled asthma with exacerbation:

- Current exacerbation

Exclusion Criteria:

Cases asthma controlled, uncontrolled excluding exacerbation, uncontrolled asthma exacerbation, and healthy volunteers:

  • Person subject to a legal protection measure
  • Vulnerable population: minors, persons under guardianship or trusteeship or persons deprived of their rights to liberty by court order.
  • women with a known pregnancy
  • Inability or refusal to comply with research requirements
  • Active or weaned smoker > 15 PA
  • Treatment with non-steroidal anti-inflammatory drugs (NSAIDs) or opioids in the 10 days prior to inclusion

Case patient with asthma:

- Coexistence of a chronic inflammatory disease other than asthma

Case healthy volunteers:

- Coexistence of an inflammatory pathology

Exclusion criteria:

Cases asthma: Pregnancy during follow-up Cases healthy volunteers: Total IgE level greater than 100 kU/L (measured on the study sample)

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
448 participants (estimated)

Study arms

  • Other
    Severe uncontrolled asthma in exacerbation

    Biological: blood sample

  • Other
    Severe uncontrolled asthma excluding exacerbation

    Biological: blood sample

  • Other
    Severe controlled asthma

    Biological: blood sample

  • Other
    Healthy volunteers (control group)

    Biological: blood sample

Interventions

  • Biologicalblood sample

    Blood sample (56mL) taken in a heparin tube

06

What researchers measure

Primary outcomes

  1. Changes in expression of one or more molecules on the surface of NK cells

    Rationale for choice of primary endpoint: Our aim is to phenotype NK cells in different groups of severe asthma patients compared with control subjects, in order to identify at least one marker of disease discrimination on these cells. We are therefore looking for previously unknown changes in the expression of one or more molecules.

    Time frame: day 1 to day 2555

Secondary outcomes

  1. Measurement of NK cell activation

    Change From Baseline in the expression of CD107, CD69 and interferon-ɣ.

    Time frame: day 1 to day 2555

  2. Measurement of NK cell-induced epithelial cell activation and viability

    Change From Baseline in epithelial cell cohesion, mucin and cytokine (IL-8, type I interferon, IL-33 and TSLP) production

    Time frame: day 1 to day 2555

07

Study locations

1 of 1 sites recruiting
  • Hôpital NORD - AP-HM, Clinique des bronches, de l'allergie et du sommeil
    Marseille, 13915, France
    Recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2023 (actual). Primary completion is estimated for Sep 2028, 60 months after the start.

Of 601 non-industry interventional studies with no phase under Asthma, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 50. This study's planned 60 months is above that.

Counting every sponsor, half of 651 studies reached it within 23 months; a quarter within 10 and three quarters within 47.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 10, 2023
First posted
Aug 29, 2023
StartActual
Sep 7, 2023
Primary completionEst.
Sep 2028
CompletionEst.
Sep 2030
Last update
Oct 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: index terms, verification date, oversight details, criteria formatting, site details and data sharing statement
1 update, last Oct 29, 2026
Show all 1 update
  1. Oct 29, 2026
    Minor edits only
    + 6 other changes: index terms, verification date, oversight details, criteria formatting, site details and data sharing statement

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06015256
Responsible party
Sponsor
First posted
Aug 29, 2023
Start date
Sep 7, 2023
Primary completion
Sep 2028 (estimated)
Completion
Sep 2030 (estimated)
Last update
Oct 29, 2026

Study contacts

Pascal Chanez, PU-PH
Contact
pascal.chanez@univ-amu.fr
+334.91.96.58.64
Catherine Duez, CRCN
Contact
catherine.duez@inserm.fr
+334.91.32.42.74

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion